Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Alexion Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alexion Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alexion Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alexion Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alexion Pharmaceuticals, Inc.'s pipeline products Reasons To Buy - Evaluate Alexion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alexion Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alexion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alexion Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alexion Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Alexion Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Alexion Pharmaceuticals, Inc. Snapshot 5 Alexion Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Alexion Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Alexion Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Alexion Pharmaceuticals, Inc. - Pipeline Products Glance 13 Alexion Pharmaceuticals, Inc. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Alexion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Alexion Pharmaceuticals, Inc. - Early Stage Pipeline Products 17 Discovery Products/Combination Treatment Modalities 17 Alexion Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 Alexion Pharmaceuticals, Inc. - Drug Profiles 19 asfotase alfa 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 eculizumab 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ALXN-1007 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ALXN-1101 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ALXN-1210 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ALXN-5500 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibodies for Undisclosed Indication 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules for Orphan Diseases 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Alexion Pharmaceuticals, Inc. - Pipeline Analysis 30 Alexion Pharmaceuticals, Inc. - Pipeline Products by Target 30 Alexion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 31 Alexion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 32 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 33 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates 34 Alexion Pharmaceuticals, Inc. - Dormant Projects 44 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 45 Discontinued Pipeline Product Profiles 45 ALXN-4100 45 Cell Therapy for Central Nervous System 45 pexelizumab 45 Alexion Pharmaceuticals, Inc. - Company Statement 46 Alexion Pharmaceuticals, Inc. - Locations And Subsidiaries 48 Head Office 48 Other Locations & Subsidiaries 48 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Alexion Pharmaceuticals, Inc., Key Information 5 Alexion Pharmaceuticals, Inc., Key Facts 5 Alexion Pharmaceuticals, Inc. - Pipeline by Indication, 2015 8 Alexion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 9 Alexion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 10 Alexion Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 11 Alexion Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12 Alexion Pharmaceuticals, Inc. - Pre-Registration, 2015 13 Alexion Pharmaceuticals, Inc. - Phase III, 2015 14 Alexion Pharmaceuticals, Inc. - Phase II, 2015 15 Alexion Pharmaceuticals, Inc. - Phase I, 2015 16 Alexion Pharmaceuticals, Inc. - Discovery, 2015 17 Alexion Pharmaceuticals, Inc. - Unknown, 2015 18 Alexion Pharmaceuticals, Inc. - Pipeline by Target, 2015 30 Alexion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 31 Alexion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 32 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 33 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 34 Alexion Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 44 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 45 Alexion Pharmaceuticals, Inc., Subsidiaries 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
